Joseph Thome
Stock Analyst at TD Cowen
(0.88)
# 3,904
Out of 5,058 analysts
19
Total ratings
37.5%
Success rate
-10.58%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Thome
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTCT PTC Therapeutics | Maintains: Hold | $50 → $63 | $78.35 | -19.59% | 3 | Nov 5, 2025 | |
| ARDX Ardelyx | Maintains: Buy | $9 → $10 | $5.69 | +75.75% | 1 | Oct 31, 2025 | |
| MIRM Mirum Pharmaceuticals | Initiates: Buy | $95 | $70.68 | +34.41% | 1 | Sep 24, 2025 | |
| DRUG Bright Minds Biosciences | Initiates: Buy | n/a | $58.60 | - | 1 | May 13, 2025 | |
| VRDN Viridian Therapeutics | Initiates: Buy | n/a | $29.64 | - | 1 | Nov 25, 2024 | |
| UTHR United Therapeutics | Maintains: Buy | $350 → $400 | $480.52 | -16.76% | 2 | Oct 21, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | n/a | $28.33 | - | 1 | Jul 2, 2024 | |
| ALKS Alkermes | Initiates: Buy | $34 | $28.63 | +18.76% | 1 | Jun 17, 2024 | |
| PRME Prime Medicine | Initiates: Buy | n/a | $3.89 | - | 1 | Apr 8, 2024 | |
| MGX Metagenomi | Initiates: Outperform | n/a | $1.62 | - | 1 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $41.71 | - | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.37 | - | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $130 | $146.59 | -11.32% | 2 | Jun 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $8.52 | - | 1 | Jan 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $8.98 | - | 1 | Nov 23, 2021 |
PTC Therapeutics
Nov 5, 2025
Maintains: Hold
Price Target: $50 → $63
Current: $78.35
Upside: -19.59%
Ardelyx
Oct 31, 2025
Maintains: Buy
Price Target: $9 → $10
Current: $5.69
Upside: +75.75%
Mirum Pharmaceuticals
Sep 24, 2025
Initiates: Buy
Price Target: $95
Current: $70.68
Upside: +34.41%
Bright Minds Biosciences
May 13, 2025
Initiates: Buy
Price Target: n/a
Current: $58.60
Upside: -
Viridian Therapeutics
Nov 25, 2024
Initiates: Buy
Price Target: n/a
Current: $29.64
Upside: -
United Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $350 → $400
Current: $480.52
Upside: -16.76%
Rapport Therapeutics
Jul 2, 2024
Initiates: Buy
Price Target: n/a
Current: $28.33
Upside: -
Alkermes
Jun 17, 2024
Initiates: Buy
Price Target: $34
Current: $28.63
Upside: +18.76%
Prime Medicine
Apr 8, 2024
Initiates: Buy
Price Target: n/a
Current: $3.89
Upside: -
Metagenomi
Mar 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $1.62
Upside: -
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $41.71
Upside: -
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $2.37
Upside: -
Jun 29, 2022
Maintains: Outperform
Price Target: $120 → $130
Current: $146.59
Upside: -11.32%
Jan 31, 2022
Initiates: Outperform
Price Target: n/a
Current: $8.52
Upside: -
Nov 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $8.98
Upside: -